These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Highlights of the third International Conference on Immunotherapy in Pediatric Oncology. Brehm C; Huenecke S; Pfirrmann V; Rossig C; Mackall CL; Bollard CM; Gottschalk S; Schlegel PG; Klingebiel T; Bader P Pediatr Hematol Oncol; 2013 Aug; 30(5):349-66. PubMed ID: 23758210 [TBL] [Abstract][Full Text] [Related]
6. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590 [TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. de la Nava D; Selvi KM; Alonso MM Front Immunol; 2022; 13():866892. PubMed ID: 35493490 [TBL] [Abstract][Full Text] [Related]
8. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Casey DL; Cheung NV Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013 [TBL] [Abstract][Full Text] [Related]
12. New developments in immunotherapy for pediatric solid tumors. Schultz LM; Majzner R; Davis KL; Mackall C Curr Opin Pediatr; 2018 Feb; 30(1):30-39. PubMed ID: 29189429 [TBL] [Abstract][Full Text] [Related]
13. Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. Haworth KB; Arnold MA; Pierson CR; Leddon JL; Kurmashev DK; Swain HM; Hutzen BJ; Roberts RD; Cripe TP Pediatr Blood Cancer; 2016 Apr; 63(4):618-26. PubMed ID: 26575538 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Ortiz MV; Roberts SS; Glade Bender J; Shukla N; Wexler LH Front Oncol; 2019; 9():108. PubMed ID: 30873384 [TBL] [Abstract][Full Text] [Related]
15. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors. Xiao L; Yeung H; Haber M; Norris MD; Somers K Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Vikas P; Borcherding N; Chennamadhavuni A; Garje R Front Oncol; 2020; 10():570. PubMed ID: 32457830 [TBL] [Abstract][Full Text] [Related]
17. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Capitini CM; Gottschalk S; Brenner M; Cooper LJ; Handgretinger R; Mackall CL Pediatr Hematol Oncol; 2011 Sep; 28(6):459-60. PubMed ID: 21854215 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the treatment of pediatric brain tumors: a narrative review. Shalita C; Hanzlik E; Kaplan S; Thompson EM Transl Pediatr; 2022 Dec; 11(12):2040-2056. PubMed ID: 36643672 [TBL] [Abstract][Full Text] [Related]
19. [Role of Immunotherapy in Pediatric Oncology]. Bajčiová V Klin Onkol; 2015; 28 Suppl 4():4S38-43. PubMed ID: 26647887 [TBL] [Abstract][Full Text] [Related]